355 related articles for article (PubMed ID: 33256913)
1. Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity.
Naeimi Kararoudi M; Tullius BP; Chakravarti N; Pomeroy EJ; Moriarity BS; Beland K; Colamartino ABL; Haddad E; Chu Y; Cairo MS; Lee DA
Semin Hematol; 2020 Oct; 57(4):201-212. PubMed ID: 33256913
[TBL] [Abstract][Full Text] [Related]
2. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell epigenetic reprogramming in tumors and potential for cancer immunotherapy.
Hojjatipour T; Maali A; Azad M
Epigenomics; 2023 Feb; 15(4):249-266. PubMed ID: 37125432
[TBL] [Abstract][Full Text] [Related]
4. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
Zhang J; Zheng H; Diao Y
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
[TBL] [Abstract][Full Text] [Related]
6. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
7. Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.
Islam R; Pupovac A; Evtimov V; Boyd N; Shu R; Boyd R; Trounson A
Cells; 2021 Apr; 10(5):. PubMed ID: 33946954
[TBL] [Abstract][Full Text] [Related]
8. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
9. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Regulation of NK Cell-Mediated Antitumor Immunity.
Xia M; Wang B; Wang Z; Zhang X; Wang X
Front Immunol; 2021; 12():672328. PubMed ID: 34017344
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
12. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
13. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO.
Chanswangphuwana C; Allan DSJ; Chakraborty M; Reger RN; Childs RW
Mol Ther; 2021 Jan; 29(1):47-59. PubMed ID: 33010232
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
16. Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.
Maia A; Tarannum M; Romee R
Stem Cells Transl Med; 2024 Mar; 13(3):230-242. PubMed ID: 38142460
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
18.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
20. Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.
Yang C; Li Y; Yang Y; Chen Z
J Immunol Res; 2020; 2020():8459496. PubMed ID: 32411806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
